Mwanzo22UA • FRA
add
BioNTech SE
Bei iliyotangulia
€ 90.95
Bei za siku
€ 90.20 - € 92.85
Bei za mwaka
€ 69.70 - € 124.60
Thamani ya kampuni katika soko
24.05B USD
Wastani wa hisa zilizouzwa
811.00
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (EUR) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 1.19B | -19.54% |
Matumizi ya uendeshaji wa biashara | 816.80M | 15.68% |
Mapato halisi | 259.50M | -43.33% |
Kiwango cha faida halisi | 21.81 | -29.55% |
Mapato kwa kila hisa | 1.08 | -43.16% |
EBITDA | 295.10M | -52.96% |
Asilimia ya kodi ya mapato | 13.84% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (EUR) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 16.78B | 1.42% |
Jumla ya mali | 22.53B | -2.07% |
Jumla ya dhima | 3.12B | 12.98% |
Jumla ya hisa | 19.41B | — |
hisa zilizosalia | 240.28M | — |
Uwiano wa bei na thamani | 1.13 | — |
Faida inayotokana na mali | 1.44% | — |
Faida inayotokana mtaji | 1.66% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (EUR) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | 259.50M | -43.33% |
Pesa kutokana na shughuli | -463.30M | -154.45% |
Pesa kutokana na uwekezaji | 606.70M | 122.51% |
Pesa kutokana na ufadhili | -7.30M | 43.41% |
Mabadiliko halisi ya pesa taslimu | 137.30M | 107.49% |
Mtiririko huru wa pesa | -174.31M | -130.65% |
Kuhusu
BioNTech SE is a global biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
2008
Tovuti
Wafanyakazi
6,772
